Información del artículo
Abstract
Patients with liver metastases from colorectal cancer (CRC) present a major public health challenge with approximately, 1.2 million cases of CRC occur yearly worldwide. Resection of colorectal liver metastases (CRLM) is the only treatment offering the possibility of cure and has been shown to provide clear survival benefits. However, only 10% to 20% of patients with CRLM are eligible for this procedure upfront. During the last decade, major advances in the management of CRLM have taken place involving three fields: oncology, interventional radiology, and surgery. These advances have increased the resectability rate to 20%–30% of cases with a 5-year survival of 35%–50%. Neoadjuvant treatment with chemotherapeutic agents such as irinotecan and oxaliplatin, and hepatic artery infusion combined with systemic therapy and biologic agents (bevacizumab, cetuximab) play an important role in increasing the number of patients eligible to secondary resection. However, with the progressive use of neoadjuvant chemotherapy further studies are necessary to answer questions such as the risk: benefit ratio in maximizing response rates versus vascular changes in the liver (current opinion still divided concerning their importance). These questions remain challenging and should not be underestimated.
In this review, we have described the current oncosurgical strategies employed in patients with resectable and non resectable CRLM, their benefits, and future treatment strategies.
Keywords:
Neoadjuvant chemotherapy
Two stage liver resection
Portal vein embolisation
Resumen
Los pacientes con metástasis hepática debida a cáncer colorrectal (CCR) constituyen un gran reto de la salud pública, con alrededor de 1,2 millones de casos de CCR anuales en todo el mundo. La resección de las metástasis hepáticas del cáncer colorrectal (MHCR) es el único tratamiento que ofrece la posibilidad de curación y ha demostrado aportar claros beneficios de supervivencia. Sin embargo, sólo entre el 10 y el 20% de los pacientes con MHCR reúnen inicialmente los requisitos para este procedimiento. Durante el último decenio, han tenido lugar importantes avances en el manejo de la MHCR, especialmente en tres campos: la oncología, la radiología intervencionista y la cirugía. Estos avances han aumentado la tasa de resecabilidad en un 20–30% de los casos, con una supervivencia a los 5 años del 35–50%. El tratamiento neoadyuvante con agentes antineoplásicos como el irinotecán y el oxaliplatino, y la infusión arterial hepática combinada con la terapia sistémica y los agentes biológicos (bevacizumab, cetuximab) desempeñan un papel importante al aumentar el número de pacientes aptos para una resección secundaria. Sin embargo, con el uso progresivo de la quimioterapia neoadyuvante, más estudios son necesarios para poder responder a temas como la relación riesgo/beneficio a la hora de maximizar las tasas de respuesta frente a los cambios vasculares en el hígado (la opinión actual continúa dividida en cuanto a la importancia de esta cuestión). Estas preguntas constituyen aún un reto y no deben subestimarse.
En esta revisión, hemos descrito las estrategias oncoquirúrgicas actuales empleadas en pacientes con MHCR en los que la resección está indicada o no, sus beneficios y las estrategias de tratamiento futuro.
Palabras clave:
Quimioterapia neoadyuvante
Hepatectomía en dos etapas
Embolización de la vena portal
El Texto completo está disponible en PDF
References
[1.]
A. Jemal, T. Murray, E. Ward, Y. Hao, J. Xu, T. Murray, et al.
Cancer statistics, 2005.
CA Cancer J Clin, 55 (2005), pp. 10-30
[2.]
International Agency for research on cancer: GLOBOCAN 2002 data [Accessed 2006 Nov 16]. Available from: http://www-dep. iarc. fr.
[3.]
R. Stangl, A. Altendorf-Hofmann, R.M. Charnley, J. Scheele.
Factors influencing thenatural history of colorectal liver metastases.
Lancet, 343 (1994), pp. 1405-1410
[4.]
G. Mentha, P. Majno, S. Terraz, L. Rubbia-Brandt, P. Gervaz, A. Andres, et al.
Treatment strategies for the management of advanced colorectal liver metastases detected synchronously with the primary tumour.
EJSO, 33 (2007), pp. 76-83
[5.]
Livermetsurvey. International registry of liver metastases of colorectal cancer.[Accessed 2010 Mar]. Available from: http://www.livermetsurvey.org.
[6.]
M. Choti, J. Sitzmann, M. Tiburi, W. Sumetchotimetha, R. Rangsin, R.D. Schulick, et al.
Trends in long term survival following liver resection for hepatic colorectal metastases.
Ann Surg, 235 (2002), pp. 759-766
[7.]
E.K. Abdalla, J.N. Vauthey, L.M. Ellis, V. Ellis, R. Pollock, K.R. Broglio, et al.
Recurrence and outcomesfollowing hepatic resection, radiofrequency ablation, and combined resection/ablation for colorectal liver metastases.
Ann Surg, 239 (2004), pp. 818-827
[8.]
Y. Fong, J. Fortner, R.L. Sun, M.F. Brennan, L.H. Blumgart.
Clinical score for predicting recurrence after hepatic resection for metastatic colorectal cancer: analysis of 1001 consecutive cases.
Ann Surg, 230 (1999), pp. 309-318
[9.]
Traitment de metastases hépatiques as cancers colorectaus,
[10.]
T.J. Gayowski, S. Iwatsuki, J.R. Madariaga, R. Selby, S. Todo, W. Irish, et al.
Experience in hepatic resection of colorectal cancer − analysis of clinical and pathological risk factors.
Surgery, 116 (1994), pp. 703-771
[11.]
M. Minagawa, M. Maltuuchi, G. Torzilli, T. Takayama, S. Kawasaki, T. Kosuge, et al.
Extension of the frontiers metastases from colorectal cancer: Long-term results.
Ann Surg, 231 (2000), pp. 487-499
[12.]
G. Ercolani, G.L. Grazi, M. Ravaioli, M. Cescon, A. Gardini, G. Varotti, et al.
Liver resection for multiple colorectal metastases: influence of parenchymal involvement and total tumor volume versus number or location on long term survival.
Arch Surg, 137 (2002), pp. 1187-1192
[13.]
J. Scheele, R. Stangl, A. Altendorf-Hofmann.
Hepatic metastases from colorectal carcinoma: impact of surgical resection on the natural history.
Br J Surg, 77 (1990), pp. 1241-1246
[14.]
R. Adam, V. Delvart, G. Pascal, A. Valeanu, D. Castaing, D. Azoulay, et al.
Rescue surgery for unresectable colorectal liver metastases downstaged by chemotherapy: a model to predict longterm survival.
Ann Surg, 240 (2004), pp. 644-658
[15.]
M. Rodgers, J. Mccall.
Surgery for colorectal liver metastases with hepatic lymph node involvement: A Systematic review.
Br J Surg, 87 (2000), pp. 1142-1155
[16.]
R. Adam, R.J. De Haas, D.A. Wicherts, T.A. Aloia, V. Delvart, D. Azoulay, et al.
Is hepatic resection justified after chemothera- py in patients with colorectal liver metastases and lymph node involvement?.
J Clin Oncol, 26 (2008), pp. 3672-3680
[17.]
J. Pfannschmidt, H. Dienemann, H. Hoffmann.
Surgical resection of pulmonary metastases from colorectal cancer: a systematic review of published series.
Ann Thorac Surg, 84 (2007), pp. 324-338
[18.]
D. Elias, G. Liberale, D. Vernerey, M. Pocard, M. Ducreux, V. Boige, et al.
Hepatic and extrahepatic colorectalmetastases: when resectable, their localization does not matter, but their total number has a prognostic effect.
Ann Surg Oncol, 12 (2005), pp. 900-909
[19.]
R. Adam, R.J. Haas, D. Wicherts, et al.
Concomitant extrahepatic in patients with colorectal liver metastases: when is there a place for surgery?.
Ann Surg, (2011),
[20.]
R. Adam, G. Pascal, D. Azoulay, K. Tanaka, D. Castaing, H. Bismuth.
Liver resection for colorectal metastases: the third hepatectomy.
Ann Surg, 238 (2003), pp. 871-883
[21.]
K. Tanaka, R. Adam, H. Shimada, D. Azoulay, F. Lévi, H. Bismuth.
Role of neoadjuvant chemotherapy in the treatment of multiple colorectal metastases to the liver.
Br J Surg, 90 (2003), pp. 963-969
[22.]
E. Mitry, A.L. Fields, H. Bleiberg, R. Labianca, G. Portier, D. Tu, et al.
Adjuvant chemotherapy after potentially curative resection of metastases from colorectal cancer: A pooled analysis of two randomized trials.
J Clin Oncol, 26 (2008), pp. 4906-4911
[23.]
B. Nordlinger, H. Sorbye, B. Glimelius, G.J. Poston, P.M. Schlag, P. Rougier, et al.
Perioperative chemotherapy with FOLFOX4 and surgery versus surgery alone for resectable liver metastases from colorectal cancer (EORTC Intergroup trial 40983): a randomised controlled trial.
Lancet, 371 (2008), pp. 1007-1016
[24.]
R. Parks, M. Gonen, N. Kemeny, W. Jarnagin, M. D’Angelica, R. DeMatteo, et al.
Adjuvant chemotherapy improves survival after resection of hepatic colorectal metastases: analysis of data from two continents.
J Am Coll Surg, 204 (2007), pp. 753-761
[25.]
B. Gruenberger, D. Tamandl, J. Schueller, W. Scheithauer, C. Zielinski, F. Herbst, et al.
Bevacizumab, capecitabine and oxaliplatin as neoadjuvant therapy for patients with potentially curable metastatic colorectal cancer.
J Clin Oncol, 26 (2008), pp. 1830-1835
[26.]
B. Gruenberger, W. Scheithauer, R. Punzengruber, C. Zielinski, D. Tamandl, T. Gruenberger.
Importance of response to neoadjuvant chemotherapy in potentially curable colorectal cancer metastases.
BMC Cancer, 8 (2008), pp. 120
[27.]
M.M. Kemeny, S. Adak, B. Gray, J.S. Macdonald, T. Smith, S. Lipsitz, et al.
Combined-modality treatment for resectable metastatic colorectal carcinoma to the liver: Surgical resection of hepatic metastases in combination with continuous infusion of chemotherapeutic-An Intergroup Study.
J Clin Oncol, 20 (2002), pp. 1499-1505
[28.]
P. Thirion, N. Wolmark, E. Haddad, M. Buyse, P. Piedbois.
Survival impact of chemotherapy in patients with colorectal metastases confined to the liver: A reanalysis of 1458 non-operable patients randomized in 22 trials and 4 meta-analysis. Meta-Analysis Group in cancer.
Ann Oncol, 10 (1999), pp. 1317-1320
[29.]
T.J. Hobday, J.W. Kugler, M.R. Mahoney, D.J. Sargent, J.A. Sloan, T.R. Fitch, et al.
Long-term survivors of metastatic colorectal cancer treated with chemotherapy only: A North central Cancer Treatment group review.
J Clin Oncol, 20 (2002), pp. 4574-4580
[30.]
S. Giacchetti, M. Itzhaki, G. Gruia, R. Adam, R. Zidani, F. Kunstlinger, et al.
Long-term survival of patient with unresectable colorectal cancer liver metastases following infusional chemotherapy with 5-fluorouacil, leucovorin, oxaliplatin and surgery.
Ann Oncol, 10 (1999), pp. 663-669
[31.]
G. Folprecht, A. Grothey, S. Alberts, H.R. Raab, C.H. Köhne.
Neoadjuvant treatment of unresectable colorectal liver metastases: Correlation between tumor response and resection rates.
Ann Oncol, 16 (2005), pp. 1311-1319
[32.]
M. Ychou, F. Viret, A. Kramar, F. Desseigne, E. Mitry, R. Guimbaud, et al.
Tritherapy with fluorouracil/leucovorin, irinotecan and oxaliplatin (FOLFIRINOX): a phase II study in colorectal cancer patients with non-resectable liver metástases.
Cancer Chemother Pharmacol, 62 (2008), pp. 195-201
[33.]
E. Van Cutsem, C.H. Köhne, E. Hitre, J. Zaluski, C.R. Chang Chien, A. Makhson, et al.
Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer.
N Engl J Med, 360 (2009), pp. 1408-1417
[34.]
C. Bokemeyer, I. Bondarenko, A. Makhson, J.T. Hartmann, J. Aparicio, F. De Braud, et al.
Fluorouracil, leucovorin, and oxaliplatin with and without cetuximab in the first-line treatment of metastatic colorectal cancer.
J Clin Oncol, 27 (2009), pp. 663-671
[35.]
J. Ocvirk, T. Brodowicz, F. Wrba, T.E. Ciuleanu, G. Kurteva, et al.
Cetuximab plus FOLFOX6 or FOLFIRI in metastatic colorectal cancer: CECOG trial.
World J Gastroenterol, 16 (2010), pp. 3133-3143
[36.]
G. Folprecht, T. Gruenberger, W.O. Bechstein, H.R. Raab, F. Lordick, J.T. Hartmann, et al.
Tumour response and secondary respectability of colorectal liver metastases following neoadjuvant chemotherapy with cetuximab: the CELIM randomized phase 2 trial.
The Lancet Oncol, 11 (2010), pp. 38-47
[37.]
R. Adam, T. Aloia, F. Lévi, D.A. Wicherts, R.J. De Haas, B. Paule, et al.
Hepatic resection after rescue cetuximab treatment for colorectal liver metastases previously refractory to conventional systemic therapy.
J Clin Oncol, 25 (2007), pp. 4593-4602
[38.]
T. De Baere, A. Roche, D. Elias, P. Lasser, C. Lagrange, V. Bousson.
Preoperative portal vein embolization for extension of hepatectomy indications.
Hepatology, 200 (1996), pp. 559-563
[39.]
D.C. Madoff, E.K. Abdalla, S. Gupta, T.T. Wu, J.S. Morris, A. Denys, et al.
Transhepatic ipsilateral rightportal vein embolization extended to segment IV: improving hypertrophy and resection outcomes with spherical particles and coils.
J Vasc Interv Radiol, 16 (2005), pp. 215-225
[40.]
E.K. Abdalla, C.C. Barnett, D. Doherty, S.A. Curley, J.N. Vauthey.
Extended hepatectomy in patients with hepatobiliary malignancies with and without preoperative portal vein embolization.
Arch Surg, 137 (2002), pp. 675-680
[41.]
J.N. Vauthey, A. Chaoui, K.A. Do, M.M. Bilimoria, M.J. Fenstermacher, C. Charnsangavej, et al.
Standardized measurement of the future liver remnant prior to extended liver resection: methodology and clinical associations.
Surgery, 127 (2000), pp. 512-519
[42.]
D. Azoulay, D. Castaing, A. Smail, R. Adam, V. Cailliez, A. Laurent, et al.
Resection of nonresectable liver metastases from colorectal cancer after percutaneous portal vein embolization.
Ann Surg, 231 (2000), pp. 480-486
[43.]
D.C. Madoff, E.K. Abdalla, J.N. Vauthey, et al.
Portal vein embolization in preparation for major hepatic resection: evolution of a new standard of care.
J Vasc Interv Radiol, 16 (2005), pp. 779-790
[44.]
D. Elias, T. De Baere, A. Roche, M. Ducreux, J. Leclere, P. Lasser.
During liver regeneration following right portal embolization the growth rate of liver metastases is more rapid than that of the liver parenchyma.
Br J Surg, 86 (1999), pp. 784-788
[45.]
N. Kokudo, K. Tada, M. Seki, H. Ohta, K. Azekura, M. Ueno, et al.
Proliferative activity of intrahepatic colorectal metastases after preoperative hemihepatic portal vein embolization.
Hepatology, 34 (2001), pp. 267-272
[46.]
D. Elias, R. Santoro, J.F. Ouellet, L. Osmak, T. De Baere, A. Roche.
Simultaneous percutaneous right portal vein embolization and left liver tumour radiofrequency ablation prior to a major right hepatic resection for bilateral colorectal metastases.
Hepatogastroenterology, 51 (2004), pp. 1788-1791
[47.]
S. Terraz, C. Constantin, P. Majno, L. Spahr, G. Mentha, C.D. Becker.
Image-guided multipolar radiofrequency ablation of liver tumours: initial clinical results.
Eur Radiol, 17 (2007), pp. 2253-2261
[48.]
R. Lencioni, D. Cioni, L. Crocetti, C. Franchini, C.D. Pina, J. Lera, et al.
Early-stage hepatocellular carcinoma in patients with cirrhosis: long-term results of percutaneous image-guided radiofrequency ablation.
Radiology, 234 (2005), pp. 961-967
[49.]
E. Berber, R. Pelley, A.E. Siperstein.
Predictors of survival after radiofrequency thermal ablation of colorectal cancer metastases to the liver: a prospective study.
J Clin Oncol, 23 (2005), pp. 1358-1364
[50.]
L. Solbiati, T. Livraghi, S.N. Goldberg, T. Ierace, F. Meloni, M. Dellanoce, et al.
Percutaneous radiofrequency ablation of hepatic metastases form colorectal cancer: long-term results in 117 patients.
Radiology, 221 (2001), pp. 159-166
[51.]
T. De Baere, B. Bessoud, C. Dromain, M. Ducreux, V. Boige, N. Lassau, et al.
Percutaneous radiofrequency ablation of hepatic tumors during temporary venous occlusion.
Am J Roentgenol, 178 (2002), pp. 53-59
[52.]
D. Elias, L. Sideris, M. Pocard, C. Dromain, T. De Baere.
Intraductal cooling of the main bile ducts during radiofrequency ablation prevents biliary stenosis.
J Am Coll Surg, 198 (2004), pp. 717-721
[53.]
S. Mulier, Y. Ni, J. Jamart, T. Ruers, G. Marchal, L. Michel.
Local recurrence after hepatic radiofrequency coagulation. Multivariate meta-analysis and review of contributing factors.
Ann Surg, 242 (2005), pp. 158-171
[54.]
T.A. Aloia, J.N. Vauthey, E.M. Loyer, D. Ribero, T.M. Pawlik, S.H. Wei, et al.
Solitary colorectal liver metastases: resection determines outcome.
Arch Surg, 141 (2006), pp. 460-467
[55.]
J. Belghiti, K. Hiramatsu, S. Benoist, P.F. Massault, A. Sauvanet, O. Farges.
Seven hundred forty-seven hepatectomies in the 1990s: an update to evaluate the actual risk of liver resection.
J Am Coll Surg, 191 (2000), pp. 38-46
[56.]
R.W. Strong, S.V. Lynch, D.R. Wall, T.H. Ong.
The safety of elective liver resection in a special unit.
Aust N Z J Surg, 64 (1994), pp. 530-534
[57.]
M.A. Choti, H.M. Bowman, H.A. Pitt, J.A. Sosa, J.V. Sitzmann, J.L. Cameron, et al.
Should hepatic resections be performed at high-volume referral centers?.
J Gastrointest Surg, 2 (1998), pp. 11-20
[58.]
Y. Fong, M. Gonen, D. Rubin, M. Radzyner, M.F. Brennan.
Longterm survival is superior after resection for cancer in highvolume centers.
Ann Surg, 242 (2005), pp. 540-547
[59.]
M.M. Chowdhury, H. Dagash, A. Pierro.
A systematic review of the impact of volume of surgery and specialization on patient outcome.
Brit J Surg, 94 (2007), pp. 145-161
[60.]
R. Adam, A. Laurent, D. Azoulay, D. Castaing, H. Bismuth.
Two stage hepatectomy: a planed strategy to treat irresecable liver tumors.
Ann Surg, 232 (2000), pp. 777-785
[61.]
R. Adam.
Chemotherapy and Surgery: new perpectives on the treatment of unresectable liver metastases.
Ann Oncol, 14 (2003), pp. ii13-ii16
[62.]
D.A. Wicherts, R. Miller, R.J. De Haas, G. Bitsakou, E. Vibert, L.A. Veilhan, et al.
Long-term results of two-stage hepatectomy for irresectable colorectal cancer liver metastase.
Ann Surg, 248 (2008), pp. 994-1005
[63.]
D. Jaeck, E. Oussoultzoglou, E. Rosso, M. Greget, J.C. Weber, P. Bachellier.
A two-stage hepatectomy procedure combined with portal vein embolization to achieve curative resection for initially unresectable multiple and bilobar colorectal liver metastases.
Ann Surg, 240 (2004), pp. 1037-1049
[64.]
D. Jaeck, P. Bachellier, M. Guiguet, K. Boudjema, J.C. Vaillant, P. Balladur, et al.
Long-term survival following resection of colorectal hepatic metastases: Association Française de Chirurgie.
Br J Surg, 84 (1997), pp. 977-980
[65.]
J. Scheele, R. Stangl, A. Altendorf-Hofmann, M. Paul.
Resection of Colorectal liver metastases.
World J Surg, 19 (1995), pp. 59-71
[66.]
H. Bismuth, D. Castaing, O.J. Garden.
Major hepatic resection under total vascular exclusion.
Ann Surg, 210 (1989), pp. 13-19
[67.]
C. Huguet, A. Gavelli, P.A. Chieco, S. Bona, J. Harb, J.M. Joseph, et al.
Liver ischemia for hepatic resection: where is the limit?.
Surgery, 111 (1992), pp. 251-259
[68.]
D. Azoulay, R. Eshkenazy, P. Andreani, D. Castaing, R. Adam, P. Ichai, et al.
In situ hypothermic perfusion of the liver versus standart total vascular exclusion for major liver resection. A controlled study.
Ann Surg, 224 (1996), pp. 155-161
[69.]
D. Azoulay, P. Andreani, U. Maggi, C. Salloum, F. Perdigao, M. Sebagh, et al.
Combined liver resection and reconstruction of the supra-renal vena cava: the Paul Brousse experience.
Ann Surg, 244 (2006), pp. 80-88
[70.]
G. Portier, D. Elias, O. Bouche, P. Rougier, J.F. Bosset, J. Saric, et al.
Multicenter randomized trial of adjuvant fluorouracil and folinic acid compared with surgery alone after resection of colorectal liver metastases: FFCD ACHBTH AURC 9002 trial.
J Clin Oncol, 24 (2006), pp. 4976-4982
[71.]
B. Nordlinger, M. Guiguet, J.C. Vaillant, P. Balladur, K. Boudjema, P. Bachellier, et al.
Surgical resection of colorectal carcinoma metastases to the liver. A prognostic scoring system to improve case selection, based on 1568 patients.
Association Francaise de Chirurgie. Cancer, 77 (1996), pp. 1254-1262
[72.]
L. Capussoti, A. Ferrero, L. Vigano, D. Ribero, R. Lo Tesoriere, R. Polastri.
Major liver resections synchronous with colorectal surgery.
Ann Surg Oncol, 14 (2007), pp. 195-201
[73.]
A. Muratore, D. Zorzi, H. Bouzari, M. Amisano, P. Massucco, E. Sperti, et al.
Asyntomatic colorectal cancer with unresectable liver metástases: immediate colorectal resection or upfront systemic chemotherapy?.
Ann Surg Oncol, 14 (2007), pp. 766-770
[74.]
R. Adam, P. Bhangui, G. Poston, D. Mirza, G. Nuzzo, E. Barroso, et al.
Is Perioperative Chemotherapy Useful for Solitary. Metachronous. Colorectal Liver Metastases?.
Ann Surg, 252 (2010), pp. 774-787
Copyright © 2011. Asociación Española de Cirujanos
